**Jordan**

Population 2018: 10 million

### Tuberculosis Profile

#### Estimates of TB burden, 2018

<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>0.5 (0.38–0.63)</td>
<td>5 (3.8–6.3)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>&lt;0.01 (&lt;0.01–0.11)</td>
<td>0.04 (0.01–0.11)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>0.036 (0.014–0.068)</td>
<td>0.36 (0.14–0.68)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>0.012 (&lt;0.01–0.017)</td>
<td>0.12 (0.08–0.17)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0 (0–&lt;0.01)</td>
<td>0.01 (0–0.02)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 6.3% (2.4–13)
- Previously treated cases: 29% (3.7–71)

#### TB case notifications, 2018

- Total new and relapse: 396
  - % tested with rapid diagnostics at time of diagnosis: 25%
  - % with known HIV status: 86%
  - % pulmonary: 71%
  - % bacteriologically confirmedººº: 46%
  - % children aged 0–14 years: 9%
  - % women: 46%
  - % men: 45%

- Total cases notified: 404

#### Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 80% (63–100)
- TB patients facing catastrophic total costs: 3% (2–4)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 39%
- Patients with known HIV status who are HIV-positive on antiretroviral therapy: 3% <1%
- MDR/RR-TB cases tested for resistance to second-line drugs: 0

#### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance ººº:
  - New cases: 73%
  - Previously treated cases: 40%

- Laboratory-confirmed cases*:
  - MDR/RR-TB: 1, XDR-TB: 0

- Patients started on treatment* **:
  - MDR/RR-TB: 1, XDR-TB: 1

#### Treatment success rate and cohort size

- New and relapse cases registered in 2017: 56% 526
- Previously treated cases, excluding relapse, registered in 2017: 91% 11
- MDR/RR-TB cases started on second-line treatment in 2016: 33% 3
- XDR-TB cases started on second-line treatment in 2016: 0

#### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 100%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 100%

#### TB financing, 2019

- National TB budget (US$ millions): 2.3
- Funding source: 26% domestic, 37% international, 37% unfunded

---

*Ranges represent uncertainty intervals
º MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Generated: 2020-03-20 Data: www.who.int/tb/data